In June 2000 to form Novartis pharmaceutical business to new global business units in oncology, transplantation, ophthalmology and mature products. The other essential products continue to be managed in the global functions (eg R & D and marketing). The new organization created a matrix structure and new roles and responsibilities for heads of business functions, CEOs of new business areas and country managers in more than 100 countries.

In June 2000 to form Novartis pharmaceutical business to new global business units in oncology, transplantation, ophthalmology and mature products. The other essential products continue to be managed in the global functions (eg R & D and marketing). The new organization created a matrix structure and new roles and responsibilities for heads of business functions, CEOs of new business areas and country managers in more than 100 countries.
«Hide

from
Srikant M. Datar,
Carin-Isabel Knoop,
Cate Reavis
Source: Harvard Business School
21 pages.
Publication Date: Jan 23, 2001. Prod #: 101030-PDF-ENG
Novartis Pharma: The Business Unit Model HBR case solution